JSA advised Suven Pharmaceuticals Limited ("Suven") (a portfolio company of Advent International) with respect to the merger of its wholly owned subsidiary, Casper Pharma Private Limited ("Casper") with and into Suven.
Suven is a listed pharmaceutical company, and scheme of amalgamation is for the merger of Casper with and into Suven in accordance with Sections 230 to 232 of the Companies Act 2013 and relevant rules. The Hon'ble National Company Law Tribunal, Mumbai Bench ("NCLT") has sanctioned the proposed merger by way of its order dated October 24, 2024. The scheme of amalgamation will be implemented in accordance with its terms.
Our Transaction Team Comprised Lead Partners – Iqbal Khan and Ambarish, Principal Associate – Krishaal Morjaria, Senior Associate – Tarini Sardesai and Associate – Ayushi Choudhary.